Methylenetetrahydrofolate reductase C677T polymorphism in patients with lung cancer in a Korean population.
ABSTRACT This study was designed to investigate an association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and the risk of lung cancer in a Korean population.
We conducted a large-scale, case-control study involving 3938 patients with newly diagnosed lung cancer and 1700 healthy controls. Genotyping was performed with peripheral blood DNA for MTHFR C677T polymorphisms. Statistical significance was estimated by logistic regression analysis.
The MTHFR C677T frequencies of CC, CT, and TT genotypes were 34.5%, 48.5%, and 17% among lung cancer patients, and 31.8%, 50.7%, and 17.5% in the controls, respectively. The MTHFR 677CT and TT genotype showed a weak protection against lung cancer compared with the homozygous CC genotype, although the results did not reach statistical significance. The age- and gender-adjusted odds ratio (OR) of overall lung cancer was 0.90 (95% confidence interval (CI), 0.77-1.04) for MTHFR 677 CT and 0.88 (95% CI, 0.71-1.07) for MTHFR 677TT. However, after stratification analysis by histological type, the MTHFR 677CT genotype showed a significantly decreased risk for squamous cell carcinoma (age- and gender-adjusted OR, 0.78; 95% CI, 0.64-0.96). The combination of 677 TT homozygous with 677 CT heterozygous also appeared to have a protection effect on the risk of squamous cell carcinoma. We observed no significant interaction between the MTHFR C677T polymorphism and age and gender or smoking habit.
This is the first reported study focusing on the association between MTHFR C677T polymorphisms and the risk of lung cancer in a Korean population. The T allele was found to provide a weak protective association with lung squamous cell carcinoma.
- [Show abstract] [Hide abstract]
ABSTRACT: Folate is essential for DNA synthesis and methylation and implicated in the process of carcinogenesis. Several studies inconclusively suggested increased folate intake may reduce ovarian cancer risk. Studies concerning the association between C677T polymorphism in methylenetetrahydrofolate reductase (MTHFR), an important enzyme in folate metabolism, and ovarian cancer risk also resulted in no agreement. The meta-analysis was conducted based on current studies to assess the association between folate intake, the MTHFR C667T polymorphism and ovarian cancer risk. 1,158 cases out of 217,309 participants from four cohort studies, 4,519 cases and 6,031 controls from four case-control studies about folate intake along with 5,617 cases and 9,808 controls from 10 publications concerning the polymorphism were pooled, respectively. We detected no significant association between total folate (RR = 1.04, 95 % confidence interval (CI) = 0.87-1.23) or dietary folate (RR = 0.88, 95 % CI = 0.75-1.05) intake and ovarian cancer risk, and also no significant relationship was found between MTHFR C677T polymorphism and ovarian cancer risk (TT vs. CC: odds ratio (OR) = 1.15, 95 % CI = 0.90-1.46; CT vs. CC: OR = 1.04, 95 % CI = 0.94-1.16). Our analysis indicated neither folate intake nor MTHFR C677T polymorphism is related to altered susceptibility of ovarian cancer.Molecular Biology Reports 10/2013; · 2.51 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Lung cancer is the most frequently occurring type of cancer worldwide and the leading cause of cancer mortality. Environmental and genetic factors play important roles in lung carcinogenesis. The aim of this meta-analysis was to investigate the association between methylenetetrahydrofolate reductase (MTHFR) polymorphism and the risk of lung cancer in East Asian populations. Related articles were identified through searching literature databases, such as PubMed, EMBASE, Web of Science, Chinese Biomedicine and CNKI. The odds ratio (OR) values in those studies were incorporated by meta-analysis to assess lung cancer susceptibility associated with the MTHFR mutation genotype. The MTHFR C677TT genotype exhibited a significantly increased risk of lung cancer compared to the MTHFR 677CC/CT genotype (OR=1.24; 95% CI, 1.01-1.52). No relationship was identified between the other MTHFR C677T genetic models and the risk of lung cancer and there was no significantly increased risk of lung cancer in A1298C genetic models. In a subgroup of hospital-based controls, according to the source of controls, the C677TT genotype exhibited a significantly increased risk of lung cancer, compared to the C677CC genotype (OR=3.01; 95% CI, 1.07-8.46). In the stratified analysis, the study indicated that the MTHFR 677TT genotype was associated with a significant increase in the risk of lung squamous carcinoma (OR=1.53; 95% CI, 1.09-2.14), whereas no association was observed between the MTHFR C677TT genotype and the risk of lung adenocarcinoma. No association was observed between MTHFR C677TT polymorphism and the risk of lung cancer when smoking was considered. In conclusion, the meta-analysis results suggested that MTHFR C677T polymorphisms exhibit a significantly increased risk of lung cancer and that the MTHFR 677TT genotype is associated with a significantly increased risk of lung squamous carcinoma.Biomedical reports. 05/2013; 1(3):440-446.
- [Show abstract] [Hide abstract]
ABSTRACT: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme involved in folate metabolism, which is essential for DNA synthesis and methylation. Genetic variations in the MTHFR gene seem to contribute to a decreased activity of MTHFR, ultimately confer increased susceptibility to cancer. As the most extensively studied polymorphism, MTHFR C677T polymorphism was shown to contribute to cancer susceptibility but the results were inconsistent. The authors performed a meta-analysis including 134 studies (46,207 cases and 69,160 controls) to address the issue. Odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) were used to assess the association. Overall, a significant elevated risk of cancer was associated with the MTHFR C677T polymorphism in T-allele versus C-allele comparison (OR = 1.06, 95 % CI 1.02-1.11, P heterogeneity < 0.001), homozygote model (OR = 1.08, 95 % CI 1.01-1.17, P heterogeneity < 0.001) and dominant model (OR = 1.05, 95 % CI 1.00-1.10, P heterogeneity < 0.001). In the stratified analyses, significantly increased cancer risks were indicated among Asians in all genetic models except for heterozygote model. Further analysis revealed that C677T was significantly associated with an increased risk of esophageal and stomach cancer. This meta-analysis supports an association between the MTHFR C677T polymorphism and increased risk of esophageal and stomach cancer, especially among Asians. Additionally, more high-quality studies and that the covariates responsible for heterogeneity should be controlled to obtain a more conclusive response about the function of MTHFR C677T in cancer.Molecular Biology Reports 04/2014; · 2.51 Impact Factor
RESEARCH ARTICLE Open Access
Methylenetetrahydrofolate reductase C677T
polymorphism in patients with lung cancer in a
Lian-Hua Cui1, Min-Ho Shin2*, Hee Nam Kim3, Hye-Rim Song2, Jin-Mei Piao2,6, Sun-Seog Kweon2,4, Jin-Su Choi2,
Woo-Jun Yun2, Young-Chul Kim5, In-Jae Oh5, Kyu-Sik Kim5
Background: This study was designed to investigate an association between methylenetetrahydrofolate reductase
(MTHFR) C677T polymorphism and the risk of lung cancer in a Korean population.
Methods: We conducted a large-scale, case-control study involving 3938 patients with newly diagnosed lung
cancer and 1700 healthy controls. Genotyping was performed with peripheral blood DNA for MTHFR C677T
polymorphisms. Statistical significance was estimated by logistic regression analysis.
Results: The MTHFR C677T frequencies of CC, CT, and TT genotypes were 34.5%, 48.5%, and 17% among lung cancer
patients, and 31.8%, 50.7%, and 17.5% in the controls, respectively. The MTHFR 677CT and TT genotype showed a weak
protection against lung cancer compared with the homozygous CC genotype, although the results did not reach
statistical significance. The age- and gender-adjusted odds ratio (OR) of overall lung cancer was 0.90 (95% confidence
interval (CI), 0.77-1.04) for MTHFR 677 CT and 0.88 (95% CI, 0.71-1.07) for MTHFR 677TT. However, after stratification
analysis by histological type, the MTHFR 677CT genotype showed a significantly decreased risk for squamous cell
carcinoma (age- and gender-adjusted OR, 0.78; 95% CI, 0.64-0.96). The combination of 677 TT homozygous with 677 CT
heterozygous also appeared to have a protection effect on the risk of squamous cell carcinoma. We observed no
significant interaction between the MTHFR C677T polymorphism and age and gender or smoking habit.
Conclusions: This is the first reported study focusing on the association between MTHFR C677T polymorphisms
and the risk of lung cancer in a Korean population. The T allele was found to provide a weak protective association
with lung squamous cell carcinoma.
Lung cancer is the leading cause of cancer-related death
worldwide. The incidence and mortality of lung cancer
have been significantly and constantly increasing over
the past two decades in Korea [1-3]. According to the
Korean National Cancer Registry, the age-standardized
incidence rate for lung cancer of Korean population was
47.5/100,000 for men and 13.3/100,000 for women in
2007 , it has become the second most common
malignant tumor following gastric cancer. The reason
for this increase in lung cancer has not been clearly
explained. Although it is well known that cigarette
smoking is the major cause of lung cancer, only 10-20%
of lifetime smokers are known to develop lung cancer.
Additionally, lung cancer is a multicellular and multi-
stage process involving a number of genetic changes in
oncogenes, suggesting that genetic factors may play an
important role in its development [4-6].
Methylenetetrahydrofolate reductase (MTHFR) is an
important enzyme in folate metabolism. A common
mutation of the MTHFR gene is the C to T transition at
nucleotide 677, which converts alanine to valine, results
in a thermo-labile enzyme with decreased activity .
The heterozygote and homozygous variant of C677T
were shown to have 65 and 30% of the enzyme activity,
respectively . The low enzymatic activity of the
* Correspondence: email@example.com
2Department of Preventive Medicine, Chonnam National University Medical
School, Gwangju, South Korea
Full list of author information is available at the end of the article
Cui et al. BMC Medical Genetics 2011, 12:28
© 2011 Cui et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
MTHFR C677T genotypic variant is associated with
DNA hypomethylation, which may induce genomic
instability or the derepression of proto-oncogenes.
To date, several studies have shown that the MTHFR
C677T polymorphism are associated with either
increased [9-12] or decreased [13-15] risk of lung cancer,
whereas others observed no association between the
MTHFR C677T genotype and genetic susceptibility to
lung cancer [16-18]. Small sample size, various ethnic
groups, diet, environment, and methodologies may be
responsible for the discrepancy. Therefore, a larger single
study is required to evaluate MTHFR C677T polymorph-
isms and the lung cancer risk in a specific population.
Additionally, to our knowledge, no previous report has
examined the effect of MTHFR C677T polymorphisms
on the risk of lung cancer in a Korean population. In the
present study, we performed a large population based
case-control study involving 3938 lung cancer patients
and 1700 healthy controls to evaluate whether MTHFR
C677T polymorphism was associated with lung cancer
risk in a Korean population. Additionally, we investigated
whether MTHFR C677T plays an interactive role in the
lung cancer risk in relation to histological subtypes and
The study population consisted of 3938 patients with
newly diagnosed lung cancer and 1700 population-based
controls. All enrolled patients were pathologically con-
firmed at Chonnam National University Hwasun Hospi-
tal between January 2000 and August 2010. Cases with
secondary or recurrent tumors were excluded.
The control group (n = 1700) consisted of participants
in the Thyroid Disease Prevalence Study , conducted
from July 2004 to January 2006 in the Yeonggwang and
Muan Counties of Jeollanam-do Province and in Namwon
City of Jeollabuk-do, Korea. A total of 4018 subjects were
randomly selected by 5-year age strata and sex. Of the
total number, 3486 were eligible subjects. Of those eligible,
1699 (48.8% of the eligible subjects; 820 men and 879
women), underwent clinical examinations. At the time of
their peripheral blood collections, all control subjects pro-
vided their informed consent to participate in this study.
This study was approved by the Institutional Review
Board of the Chonnam National University Hwasun Hos-
pital in Hwasun, South Korea. At the time of their periph-
eral blood collections, all case and control subjects
provided their informed consent to participate in this
blood using a QIAamp DNA Blood Mini Kit (Qiagen,
DNAwasextracted from peripheral
Valencia, CA, USA) according to the manufacturer’s
protocol. Genotyping was performed by polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) or real-time PCR. The genotyping protocol
for PCR-RFLP was adapted from Frosst et al. . After
HinfI (Takara, Tokyo, Japan) restriction enzyme diges-
tion, samples were run on a 10% polyacrylamide gel
(19:1) using Microtitre Array Diagonal Gel Electrophor-
esis (MADGE; MadgeBio, Grantham and Southampton,
UK). Genotyping by real-time PCR was performed by
allelic discrimination using dual-labeled probes contain-
ing locked nucleic acids (LNA) in a real-time PCR assay.
PCR primers and LNA probes were designed and
synthesized by Integrated DNA Technologies (IDT, Cor-
alville, IA, USA). Primers producing a 104-bp amplicon
were as follows: forward, 5’-CTTTGAGGCTGACCT-
GAAGC-3’ and reverse, 5’-TCACAAAGCGGAAGAA
TGTG-3’. Dual-labeled LNA hybridization probes were
5’-FAM-ATG GcT ccc-BHQ1-3’ for the C allele and
5’-cy5-cgA CTc cCg C-BHQ2-3’ for the T allele (LNA
bases are denoted in upper case, and single nucleotide
polymorphisms are underlined). Real-time PCR was per-
formed using a Rotor-Gene 3000 multiplex system (Cor-
bett Research, Sydney, Australia) in a 10-μL reaction
volume containing 200 nM PCR primer, 10-10 nM each
probe, 0.5 U f-taq polymerase (Solgent, Daejeon, Korea),
and 40 ng of genomic DNA. In 24 subjects, the results
of PCR-RFLP were compared with those from real-time
PCR, and the resulting concordance rate was 100%.
The statistical significance of differences between the
patient and control groups was estimated by logistic
regression analysis. Adjusted odds ratios (OR) were cal-
culated with a logistic regression model that controlled
for gender and age and are given with 95% confidence
intervals (CI). Subjects with the wild-type genotypes
(MTHFR 677CC) were considered to be at baseline risk.
The expected frequency of control genotypes was
checked by the Hardy-Weinberg equilibrium test. The
heterogeneity was tested by multivariate logistic regres-
sion model. Subjects for whom there were missing data
for smoking or histological type were excluded in inter-
action and subgroup analyses related to these variables.
All analyses were performed using the Statistical Pack-
age for the Social Sciences software (ver. 13.0; SPSS,
Chicago, IL, USA).
The characteristics of the study population are pre-
sented in Table 1. In total, 3938 cases and 1700 controls
were included in these analyses. The 3938 lung cancer
cases consisted of 1523 adenocarcinomas, 1519 squa-
mous cell carcinomas, 574 small cell carcinomas, and
Cui et al. BMC Medical Genetics 2011, 12:28
Page 2 of 6
322 other types, including 75 large cell cancers and 247
mixed types. The mean age of patients with lung cancer
was significantly higher than the control group. A statis-
tically significant gender difference was also found
between patients with lung cancer and healthy controls;
the control group had more females. The proportion of
smokers in lung cancer cases was higher than in the
Table 2 shows the genotype distributions for MTHFR
C677T and their ORs and 95% CIs in lung cancer. The
distribution of the MTHFR C677T gene polymorphisms
in the controls was calculated by the Hardy-Weinberg
equilibrium. The MTHFR C677T frequencies of CC,
CT, and TT genotypes were 34.5%, 48.5%, and 17.0% in
lung cancer, and 31.8%, 50.7%, and 17.5% in the con-
trols, respectively. The frequencies of combination for
677 CT heterozygous and 677 TT homozygous were
observed 65.4% in lung cancer and 68.2% in the con-
trols. Compared with the MTHFR 677 CC genotype, the
TT and CT genotypes showed a protective effect for the
risk of lung cancer when adjustments were made for age
and gender, overall TT versus CC (OR = 0.88; 95% CI =
0.71-1.07) and overall CT versus CC (OR = 0.90; 95%
CI = 0.77-1.04); however, the results did not reach sta-
Table 3 shows subgroup analysis by gender, age and
histological type for the MTHFR C677T polymorphisms.
When the MTHFR 677CC genotype was used as the
reference group, the MTHFR 677 CT genotype were
associated with a significantly reduced risk in squamous
cell carcinoma (OR = 0.78; 95% CI = 0.64- 0.96), the
combined variant genotypes (677 CT + TT) also showed
a protect effect on the risk of squamous cell carcinoma
(OR = 0.79; 95% CI = 0.65- 0.95), while there was no
significant association in other histological types of lung
cancer. There were no heterogeneities among subgroups
of gender (male, female), age (age ≤65, age > 65), smok-
ing (never smoker, ever smoker), histological type (ade-
nocarcinoma, squamous cell carcinoma, small cell
carcinoma, other types). Nor did we find evidence for
an interaction between the MTHFR C677T polymorph-
isms and age and gender or smoking habit.
The current study represents the largest sample (3938
lung cancer patients and 1700 controls) of a single
population reported to evaluate a possible association
between MTHFR C677T gene polymorphism and sus-
ceptibility to lung cancer. To our knowledge, this is also
the first report to examine the association between
MTHFR C677T polymorphisms and susceptibility to
lung cancer in a Korean population. We found that the
MTHFR 677 CT and TT showed weak protection for
overall lung cancer, although the results were not statis-
tically significant. However, by histological subtype, we
found significant protection of the MTHFR CT geno-
type for squamous cell carcinoma risk.
The combination of 677 TT homozygous with 677 CT
heterozygous also appeared to have a protection effect
on the risk of squamous cell carcinoma. We observed
no significant interactions between the MTHFR C677T
polymorphism and smoking, gender, or age.
Results of several studies examining the role of the
MTHFR C677T polymorphism in lung cancer suscept-
ibility have been inconsistent. Liu et al.  and Jeng
et al.  in Taiwan and Suzuki et al.  in Japan
showed that the MTHFR 677 TT genotype was asso-
ciated with a decreased risk of lung cancer. However,
Siemianowicz et al.  in Poland, Hung et al.  in
Central Europe, and Shen et al.  in China showed
that individuals with MTHFR TT genotype had an
increased risk of lung cancer versus those with the wild-
type homozygous variant, while a recent meta-analysis
by Mao et al.  based on eight case-control study
suggested no evidence for a major role of the MTHFR
C677T polymorphisms in carcinogenesis of lung cancer.
Table 1 General characteristics of subjects
CharacteristicsCases n (%) Controls n (%)
Age(mean ± SD)*
> 65 years
64.8 ± 9.6
52.2 ± 14.3
SD, standard deviation; ADC, adenocarcinoma; SQC, squamous cell carcinoma;
SCLC, small cell lung cancer; others, large cell carcinoma and mixed types;
*, p < 0.01.
Table 2 Distribution of MTHFR C677T and their
association with lung cancer risk
MTHFR C677T Lung cancer n (%)Control n (%) ORa
aAdjusted for age, gender; OR, odds ratio; CI, confidence interval.
Cui et al. BMC Medical Genetics 2011, 12:28
Page 3 of 6
Small sample size, various ethnic groups, diet, environ-
ment, and methodologies might be responsible for the
The pathogenesis of adenocarcinoma is considered to
be somewhat different from that of squamous cell carci-
nomas, and whether the effect of MTHFR C677T poly-
morphism differs by lung cancer histology remains
unclear. We performed a stratification analysis by
histological type, which is lacking in most previous stu-
dies, and found that the MTHFR 677 CT genotype was
associated with a significantly decreased risk for lung
squamous cell carcinoma (OR = 0.78, 95%CI = 0.64-
0.96), supporting the potential effect of MTHFR C677T
polymorphism on lung squamous cell carcinoma. In
other histological type of lung cancer, such as adenocar-
cinoma and small cell lung cancer, we found no associa-
tion between C677T MTHFR genotype and lung cancer
risk. A similar result was seen in a Japanese study in
which no effect of MTHFR C677T polymorphism on
the risk of overall lung cancer was evident, but on
histology based analysis, the MTHFR 677T allele was
associated with a reduced risk of squamous/small cell
carcinoma . While Siemianowicz et al.  reported
that the 677TT genotype was associated with a signifi-
cantly higher risk of non-small cell lung cancer.
The role of MTHFR polymorphisms in modulating can-
cer risk is associated with folate status. Under adequate
folate conditions, the protective effect of the 677TT geno-
type turns to a situation of elevated risk of lung cancer
among MTHFR 677TT genotype with low folate intakes.
A recent meta-analysis by Boccia et al. , which
included stratified analysis according to dietary folate
intake, showed an increased risk for individuals with low
folate intake (OR = 1.28, 95% CI = 0.97-1.68 for lung) ver-
sus high folate intake (OR = 0.94, 95% CI = 0.79-1.12 for
lung). Plasma folate level might be relatively high among
Korean adults; the median plasma folate was 22.7 nmol/L
in our population based controls, which is higher than
that in Chinese population , and also higher than that
in populations from15 European countries (folate status
ranged from 6.3 to 20.1 nmol/L) . In addition, folate
intake seems also fairly high among Korean population;
the average of folate intake in Korea is about 347 μg/day
. This level is higher than the average intake in most
European countries, except for United Kingdom . This
might provide a partial explanation why the MTHFR 677
mutations were found to protect against lung cancer, espe-
cially in lung squamous cell carcinoma in our study.
Moreover, our recent study found a protective effect of
MTHFR 677 T allele on the risk of gastric and colorectal
cancer in a Korean population .
In our study, there was no significant gender differ-
ence in the effect of MTHFR C677T polymorphism on
lung cancer risk. Our results seem to differ from those
of the Shi et al.  study in Houston, TX, USA, which
reported that the MTHFR 677TT genotype in women
was associated with a decreased lung cancer risk com-
pared with carriers of the MTHFR 677CC genotype.
Cigarette smoking is a known risk factor for lung can-
cer, and smokers may tend to have lower levels of
serum and produce a localized deficiency of folic acid.
We further examined the effects of MTHFR C677T in
subgroups according to smoking status and found no
interaction between the MTHFR C677T polymorphism
Table 3 Subgroup analysis for the MTHFR C677T polymorphisms
CT vs. CC
TT vs. CC
CT+TT vs. CC
SCLC, small cell lung cancer; SQC, squamous cell carcinoma; ADC, adenocarcinoma; others, large cell carcinoma and mixed types.
ORa: odds ratio adjusted for age and gender, CI, confidence interval.
Pb: p values for heterogeneity.
Cui et al. BMC Medical Genetics 2011, 12:28
Page 4 of 6
and smoking. Our results seem somewhat similar to
the results of Vineis, et al. , which showed that the
MTHFR C677T polymorphism had no any association
in both smokers and nonsmokers. However, a benefi-
cial effect of the MTHFR TT genotype on the risk of
lung cancer was observed in those with heavy smokers;
Suzuki et al.  in Japan found that MTHFR 677T
alleles were associated with reduced risk of squamous/
small cell carcinomas, especially among heavy smokers
with the MTHFR 677T allele. Liu et al.  in Taiwan
observed that smokers carrying the MTHFR 677 T
allele showed a significantly decreased risk of lung
It is well known that familial aggregation of lung cancer
could increase the risk of lung cancer, and a high con-
sumption of vegetables and fruits is associated with a
reduced risk of lung cancer. However, we have no infor-
mation on the accuracy of reported family history of can-
cer, dietary folate intake or detailed data on the
environmental tobacco exposure risk factors for lung can-
cer. Thus, we cannot evaluate the relationship between
gene-environment interactions. Another limitation of the
present study is that the case group was composed of lung
cancer patients who were enrolled from hospital, which
could not be representative the general population.
Our present large case-control study in Korea found a
protective effect of the MTHFR C677T variant genotype
for lung squamous cell carcinoma and suggested that
the effects of MTHFR C677T polymorphism may be
involved in the development of lung cancer for Korean
1Department of Public Health, Qingdao University Medical College, Qingdao,
China.2Department of Preventive Medicine, Chonnam National University
Medical School, Gwangju, South Korea.3Genome Research Center for
Hematopoietic Diseases, Chonnam National University Hwasun Hospital,
Hwasun, Jeollanam-do, South Korea.4Jeonnam Regional Cancer Center,
Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do,
South Korea.5Lung and Esophageal Cancer Clinic, Chonnam National
University Medical School, Hwasun Hospital, Hwasun, Jeollanam-do, South
Korea.6Yanbian University Medical College, 121 Juzi Street, Yanji, Jilin
MHS planned the analysis. CLH performed in the study design and drafted
the manuscript. HNK and HRS participated in the experiments. JMP
performed data analysis. YCK, IJO and KSK provided clinical material. SSK,
JSC, and WJY participated in its design and coordination. All authors read
and approved the final manuscript.
The authors declare that they have no competing interests.
Received: 15 November 2010 Accepted: 22 February 2011
Published: 22 February 2011
1.Jee SH, Kim IS, Suh I, Shin D, Appel LJ: Projected mortality from lung
cancer in South Korea, 1980-2004. Int J Epidemiol 1998, 27(3):365-369.
2.Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS: Cancer
statistics in Korea: incidence, mortality and survival in 2006-2007.
J Korean Med Sci 25(8):1113-1121.
3.Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK,
Pisani P, Park JG: Nationwide cancer incidence in Korea, 1999~2001; first
result using the national cancer incidence database. Cancer Res Treat
4.Mattson ME, Pollack ES, Cullen JW: What are the odds that smoking will
kill you? Am J Public Health 1987, 77(4):425-431.
5. Shields PG: Molecular epidemiology of smoking and lung cancer.
Oncogene 2002, 21(45):6870-6876.
6.Shields PG, Harris CC: Cancer risk and low-penetrance susceptibility
genes in gene-environment interactions. J Clin Oncol 2000,
7. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH,
Selhub J, Rozen R: Relation between folate status, a common mutation in
methylenetetrahydrofolate reductase, and plasma homocysteine
concentrations. Circulation 1996, 93(1):7-9.
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ,
den Heijer M, Kluijtmans LA, van den Heuvel LP, et al: A candidate genetic
risk factor for vascular disease: a common mutation in
methylenetetrahydrofolate reductase. Nature genetics 1995, 10(1):111-113.
9.Hung RJ, Hashibe M, McKay J, Gaborieau V, Szeszenia-Dabrowska N,
Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates I, et al: Folate-related
genes and the risk of tobacco-related cancers in Central Europe.
Carcinogenesis 2007, 28(6):1334-1340.
10.Shen M, Rothman N, Berndt SI, He X, Yeager M, Welch R, Chanock S,
Caporaso N, Lan Q: Polymorphisms in folate metabolic genes and lung
cancer risk in Xuan Wei, China. Lung Cancer 2005, 49(3):299-309.
11. Siemianowicz K, Gminski J, Garczorz W, Slabiak N, Goss M, Machalski M,
Magiera-Molendowska H: Methylenetetrahydrofolate reductase gene
C677T and A1298C polymorphisms in patients with small cell and non-
small cell lung cancer. Oncol Rep 2003, 10(5):1341-1344.
12. Zhang XM, Miao XP, Tan W, Qu SN, Sun T, Zhou YF, Lin DX: Association
between genetic polymorphisms in methylentetrahydrofolate reductase
and risk of lung cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005,
13. Jeng YL, Wu MH, Huang HB, Lin WY, You SL, Chu TY, Chen CJ, Sun CA: The
methylenetetrahydrofolate reductase 677C–>T polymorphism and lung
cancer risk in a Chinese population. Anticancer Res 2003,
Liu CS, Tsai CW, Hsia TC, Wang RF, Liu CJ, Hang LW, Chiang SY, Wang CH,
Tsai RY, Lin CC, et al: Interaction of methylenetetrahydrofolate reductase
genotype and smoking habit in Taiwanese lung cancer patients. Cancer
Genomics Proteomics 2009, 6(6):325-329.
15.Suzuki T, Matsuo K, Hiraki A, Saito T, Sato S, Yatabe Y, Mitsudomi T, Hida T,
Ueda R, Tajima K: Impact of one-carbon metabolism-related gene
polymorphisms on risk of lung cancer in Japan: a case control study.
Carcinogenesis 2007, 28(8):1718-1725.
16.Heijmans BT, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG,
Kromhout D, Feskens EJ, Slagboom PE: A common variant of the
methylenetetrahydrofolate reductase gene (1p36) is associated with an
increased risk of cancer. Cancer Res 2003, 63(6):1249-1253.
17.Shen H, Spitz MR, Wang LE, Hong WK, Wei Q: Polymorphisms of
methylene-tetrahydrofolate reductase and risk of lung cancer: a case-
control study. Cancer Epidemiol Biomarkers Prev 2001, 10(4):397-401.
18. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, Peluso M,
Airoldi L, Overvad K, Raaschou-Nielsen O, et al: Genetic susceptibility
according to three metabolic pathways in cancers of the lung and bladder
and in myeloid leukemias in nonsmokers. Ann Oncol 2007, 18(7):1230-1242.
19.Kim HN, Lee IK, Kim YK, Tran HT, Yang DH, Lee JJ, Shin MH, Park KS,
Shin MG, Choi JS, et al: Association between folate-metabolizing pathway
polymorphism and non-Hodgkin lymphoma. Br J Haematol 2008,
20.Mao R, Fan Y, Jin Y, Bai J, Fu S: Methylenetetrahydrofolate reductase gene
polymorphisms and lung cancer: a meta-analysis. J Hum Genet 2008,
Cui et al. BMC Medical Genetics 2011, 12:28
Page 5 of 6
21. Boccia S, Boffetta P, Brennan P, Ricciardi G, Gianfagna F, Matsuo K, van
Duijn CM, Hung RJ: Meta-analyses of the methylenetetrahydrofolate
reductase C677T and A1298C polymorphisms and risk of head and neck
and lung cancer. Cancer Lett 2009, 273(1):55-61.
Hao L, Ma J, Zhu J, Stampfer MJ, Tian Y, Willett WC, Li Z: High prevalence
of hyperhomocysteinemia in Chinese adults is associated with low
folate, vitamin B-12, and vitamin B-6 status. J Nutr 2007, 137(2):407-413.
Dhonukshe-Rutten RA, de Vries JH, de Bree A, van der Put N, van
Staveren WA, de Groot LC: Dietary intake and status of folate and vitamin
B12 and their association with homocysteine and cardiovascular disease
in European populations. Eur J Clin Nutr 2009, 63(1):18-30.
Lee HC, Jeong YM, Lee SH, Cha KY, Song SH, Kim NK, Lee KW, Lee S:
Association study of four polymorphisms in three folate-related enzyme
genes with non-obstructive male infertility. Hum Reprod 2006,
Cui LH, Shin MH, Kweon SS, Kim HN, Song HR, Piao JM, Choi JS, Shim HJ,
Hwang JE, Kim HR, et al: Methylenetetrahydrofolate reductase C677T
polymorphism in patients with gastric and colorectal cancer in a Korean
population. BMC Cancer 10:236.
Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, Wei Q: Sex
differences in risk of lung cancer associated with methylene-
tetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers
Prev 2005, 14(6):1477-1484.
The pre-publication history for this paper can be accessed here:
Cite this article as: Cui et al.: Methylenetetrahydrofolate reductase
C677T polymorphism in patients with lung cancer in a Korean
population. BMC Medical Genetics 2011 12:28.
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
Cui et al. BMC Medical Genetics 2011, 12:28
Page 6 of 6